Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.
Birmingham, United States. In Curr Oncol Rep, Sep 2015
Newer ADCs, such as polatuzumab vedotin (targeting CD79b), pinatuzumab vedotin (targeting CD22), inotuzumab ozogamicin (targeting CD19), SAR3419 (targeting CD19), IMGN529 (targeting CD37), and SGN-CD19A (targeting CD19), have shown promising preclinical and early clinical activity.
Coordinated loss of microRNA group causes defenseless signaling in malignant lymphoma.
Tokyo, Japan. In Sci Rep, 2014
Conventional screening and RISC profiling identify multiple targets (CD79B, SYK, PKCβII, PLCγ1, IKKβ, NIK, MYD88, PI3K class I (α/β/δ/γ), RasGRP3); signaling network habitually faces interference composed by miRNA group in normal B cells.
Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice.
Köln, Germany. In Acta Neuropathol, 2014
Several important pathways, i.e., the B cell receptor (BCR), the toll-like receptor, and the nuclear factor-κB pathway, are activated frequently due to genetic changes affecting genes like CD79B, SHIP, CBL, BLNK, CARD11, MALT1, BCL2, and MYD88.
B-cell receptor signaling as a driver of lymphoma development and evolution.
Bethesda, United States. In Semin Cancer Biol, 2013
In a number of B-cell malignancies, activating mutations in signal transduction components of the BCR pathway have been identified; prominent examples are activated B-cell-like (ABC) diffuse large B-cell lymphomas (DLBCL) that carry mutations in CD79B and CARD11 and display chronic active BCR signaling resulting in constitutive activation of the NF-κB pathway.
The role of Ig-α/β in B cell antigen receptor internalization.
Vancouver, Canada. In Immunol Lett, 2010
Data indicate that both the Igalpha and the Igbeta cytoplasmic domains alone are sufficient for trafficking to lysosomal compartments, and are unaffected by mutation of 4 amino acid residues within their respective ITAMs.
Primary B cell immunodeficiencies: comparisons and contrasts.
Memphis, United States. In Annu Rev Immunol, 2008
Mutations in Btk, components of the pre-B cell and B cell receptor (lambda5, Igalpha, Igbeta), or the scaffold protein BLNK account for approximately 90% of patients with defects in early B cell development.